Abbisko Therapeutics Co, Ltd

This study tests an experimental drug called ABSK141 in about 400 adults with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to find a safe dose and see if the drug can shrink tumors or slow their growth. Participants must be 18 or older and have cance…

This early-stage study tests an experimental drug called ABSK-011 in about 200 people with advanced solid tumors, especially liver cancer. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Participants must have tried other tre…

This early-phase study tests a new drug called ABSK131 in people with advanced solid tumors that have a missing MTAP gene. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors or slow their growth. About 266 adults who have tried other tr…

This early-stage study tests an experimental pill called ABSK021 in people with advanced solid tumors (including a rare joint tumor called TGCT) who have run out of standard options. The main goal is to check safety and find the right dose, while also seeing if the drug can shrin…

This study tests a new drug called ABSK-011 for people with advanced liver cancer that has not responded to previous treatments. The drug targets a specific protein (FGF19) found in some tumors. About 141 participants will receive either ABSK-011 or a placebo, both with standard …

This study follows 260 children with achondroplasia (a common form of dwarfism) for up to 2 years. Researchers measure height, body proportions, medical issues, and quality of life to learn more about how the condition progresses naturally. No treatment is given—the goal is simpl…